NO995002D0 - Modifiserte TNF-<alfa>-molekyler, DNA som koder for slike modifiserte TNF-<alfa>-molekyler og vaksiner omfattende slike TNF-<alfa>-molekyler og DNA - Google Patents

Modifiserte TNF-<alfa>-molekyler, DNA som koder for slike modifiserte TNF-<alfa>-molekyler og vaksiner omfattende slike TNF-<alfa>-molekyler og DNA

Info

Publication number
NO995002D0
NO995002D0 NO995002A NO995002A NO995002D0 NO 995002 D0 NO995002 D0 NO 995002D0 NO 995002 A NO995002 A NO 995002A NO 995002 A NO995002 A NO 995002A NO 995002 D0 NO995002 D0 NO 995002D0
Authority
NO
Norway
Prior art keywords
alpha
molecules
tnfalpha
tnf
modified
Prior art date
Application number
NO995002A
Other languages
English (en)
Other versions
NO995002L (no
Inventor
Martin Roland Jensen
Soeren Mouritsen
Henrik Elsner
Iben Dalum
Original Assignee
Ferring Farma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Farma Lab filed Critical Ferring Farma Lab
Publication of NO995002D0 publication Critical patent/NO995002D0/no
Publication of NO995002L publication Critical patent/NO995002L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO995002A 1997-04-15 1999-10-14 Modifiserte TNF-<alfa>-molekyler, DNA som koder for slike modifiserte TNF-<alfa>-molekyler og vaksiner omfattende slike TNF- <alfa>-molekyler og DNA NO995002L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK41897 1997-04-15
US4418797P 1997-04-24 1997-04-24
PCT/DK1998/000157 WO1998046642A1 (en) 1997-04-15 1998-04-15 MODIFIED TNFα MOLECULES, DNA ENCODING SUCH MODIFIED TNFα MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFα MOLECULES AND DNA

Publications (2)

Publication Number Publication Date
NO995002D0 true NO995002D0 (no) 1999-10-14
NO995002L NO995002L (no) 1999-12-15

Family

ID=8093298

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995002A NO995002L (no) 1997-04-15 1999-10-14 Modifiserte TNF-<alfa>-molekyler, DNA som koder for slike modifiserte TNF-<alfa>-molekyler og vaksiner omfattende slike TNF- <alfa>-molekyler og DNA

Country Status (30)

Country Link
US (1) US7118750B1 (no)
EP (1) EP0975668B1 (no)
JP (1) JP2001521386A (no)
KR (1) KR100522289B1 (no)
CN (1) CN1178955C (no)
AR (1) AR012427A1 (no)
AT (1) ATE326481T1 (no)
AU (1) AU743400B2 (no)
BR (1) BR9811462A (no)
CA (1) CA2289476A1 (no)
CZ (1) CZ9903657A3 (no)
DE (1) DE69834556T2 (no)
DK (1) DK0975668T3 (no)
EE (1) EE9900461A (no)
ES (1) ES2264569T3 (no)
HK (1) HK1022918A1 (no)
HR (1) HRP980203B1 (no)
HU (1) HUP0001930A3 (no)
IL (1) IL132281A0 (no)
NO (1) NO995002L (no)
NZ (1) NZ337955A (no)
PL (1) PL194221B1 (no)
RU (1) RU2241715C2 (no)
SI (1) SI0975668T1 (no)
SK (1) SK285639B6 (no)
TR (1) TR199902562T2 (no)
TW (1) TW510921B (no)
UA (1) UA72440C2 (no)
WO (1) WO1998046642A1 (no)
ZA (1) ZA983148B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
DK1159003T3 (da) * 1999-03-02 2011-02-07 Centocor Inc Anti-tnfalfa-antistoffer til terapi af steroid-resistent astma
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
US7056512B1 (en) 1999-07-20 2006-06-06 Pharmexa A/S Method for down-regulating GDF-8 activity
EP1296709A1 (en) * 2000-06-21 2003-04-02 Ferring BV Solubilised protein vaccines
EP1485122A2 (en) * 2002-03-11 2004-12-15 Pharmexa A/S Novel application of vaccination against tnf-alpha
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
US7892558B2 (en) 2004-02-27 2011-02-22 Vaxconsulting Isolated TNF-alpha peptide and pharmaceutical composition thereof
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
KR20100084623A (ko) * 2007-09-25 2010-07-27 인터벳 인터내셔널 비.브이. 골관절염 치료용 백신
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP6292748B2 (ja) 2009-11-05 2018-03-14 ザ ユーエービー リサーチ ファンデーション 基底細胞様遺伝子型癌の処置
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CA2820837A1 (en) 2010-12-08 2012-06-14 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性Ａ−βに対する抗体を生成させるための能動免疫
CN103376327A (zh) * 2012-04-28 2013-10-30 通用电气公司 检测抗体或融合蛋白的浓度的方法
AU2016256876B2 (en) 2015-05-05 2021-02-04 Rubicon Biotechnology Llc Cancer immunotherapeutic
CN106279403B (zh) * 2016-08-16 2019-06-11 长春市海兰深生物医学技术有限公司 一种检测天然肺癌相关抗体的组合物、试剂盒和方法
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750056T2 (de) * 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
DE3843534A1 (de) 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU634379B2 (en) 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Also Published As

Publication number Publication date
AR012427A1 (es) 2000-10-18
HRP980203A2 (en) 1998-12-31
ES2264569T3 (es) 2007-01-01
TR199902562T2 (xx) 2000-02-21
HUP0001930A3 (en) 2001-10-29
ATE326481T1 (de) 2006-06-15
NZ337955A (en) 2000-09-29
UA72440C2 (en) 2005-03-15
NO995002L (no) 1999-12-15
EP0975668A1 (en) 2000-02-02
RU2241715C2 (ru) 2004-12-10
PL194221B1 (pl) 2007-05-31
AU7030398A (en) 1998-11-11
US7118750B1 (en) 2006-10-10
SI0975668T1 (sl) 2007-02-28
DE69834556D1 (de) 2006-06-22
HRP980203B1 (en) 2003-04-30
JP2001521386A (ja) 2001-11-06
CN1178955C (zh) 2004-12-08
HUP0001930A2 (hu) 2000-09-28
HK1022918A1 (en) 2000-08-25
DK0975668T3 (da) 2006-09-25
SK140999A3 (en) 2000-06-12
WO1998046642A1 (en) 1998-10-22
EP0975668B1 (en) 2006-05-17
IL132281A0 (en) 2001-03-19
SK285639B6 (sk) 2007-05-03
EE9900461A (et) 2000-06-15
CZ9903657A3 (cs) 2001-09-12
ZA983148B (en) 1999-10-15
TW510921B (en) 2002-11-21
KR20010006416A (ko) 2001-01-26
CA2289476A1 (en) 1998-10-22
AU743400B2 (en) 2002-01-24
DE69834556T2 (de) 2007-05-10
CN1252809A (zh) 2000-05-10
PL336295A1 (en) 2000-06-19
BR9811462A (pt) 2000-09-12
KR100522289B1 (ko) 2005-10-19

Similar Documents

Publication Publication Date Title
NO995002D0 (no) Modifiserte TNF-&lt;alfa&gt;-molekyler, DNA som koder for slike modifiserte TNF-&lt;alfa&gt;-molekyler og vaksiner omfattende slike TNF-&lt;alfa&gt;-molekyler og DNA
HUP9801122A2 (hu) Osteoprotegerin
BR0213565A (pt) Anticorpo de anti-tnf alfa modificado
HRP20040712B1 (hr) Anti-amiloidna beta antitijela i njihova uporaba
DK0479948T3 (da) Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
BR9408006A (pt) Molécula de ácido nucléico isolada e purificada vetor e vetor de express o adaptados para transformaçao de hospedeiro hospedeiro transformado proteina receptora &#34;transferrin&#34; recombinante ou fragmento ou análogo da mesma proteina Tbpl purificada e isolada proteina Tbp2 purificada e isolada peptídeo composiç o imunogênica vetor ativo para fornecimento de proteina receptora &#34;transferrin&#34; vetor de plasmideo linhagem de haemophilus processo para produzir proteina Tbp2 ou Tbpl purificada e isolada
NO20011381L (no) Preparater av streptokokk C&lt;beta&gt;-protein
ATE371671T1 (de) Rekombinantes allergen, seine fragmente und die damit korrespondierenden dna-moleküle, vektoren, und diese dna-moleküle enthaltenden wirte, und dignostische und therapeutische verwendungen besagter allergene und fragmente
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
JPH05506247A (ja) ヒトγインターフェロンのアンタゴニスト
HUP0100267A2 (hu) Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények
ATE357526T1 (de) Modifizierte hcv peptid-impfstoffe
DK0440321T3 (da) Epididymis-specifikke polypeptider og deres anvendelse
DK0805204T3 (da) Bitestikel - specifikt receptorprotein og anvendelse heraf
KR930703444A (ko) 어류 황체화 호르몬-방출 호르몬 동족체
ATE274059T1 (de) Transferrinrezeptorgene
JPWO2006035815A1 (ja) 熱帯熱マラリア原虫のエノラーゼ蛋白質の部分ペプチドの製造方法
Fischer et al. Synthetic peptide antigens of tetanus toxin
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof
BR0116420A (pt) proteìnas moduladoras de receptores de glutamato e moléculas de ácidos nucléicos e aplicações das mesmas
AU2003278501A8 (en) Use of poly-alpha2,8-sialic acid mimetic peptides to modulate ncam functions.
AR036104A1 (es) Un receptor acoplado a la proteina g, gave3
BR0213029A (pt) Receptor acoplado por proteìna g, gave10
GEP20002244B (en) Osteoprotegerin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application